Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
MITSUBISHI TANABE PHARMA CORPORATION et al v. SANDOZ INC. et al
Case Number:
3:17-cv-05319
Court:
Nature of Suit:
Patent - Abbreviated New Drug Application(ANDA)
Judge:
Firms
- Hill Wallack
- Kasowitz Benson
- Lerner David
- Paul Hastings
- Quinn Emanuel
- Saiber LLC
- Saul Ewing
- Stone Conroy LLC
- White & Case
Companies
- Aurobindo Pharma Ltd.
- Mitsubishi Tanabe Pharma Corp.
- Prinston Pharmaceutical Inc.
- Zydus Pharmaceuticals Inc.
Sectors & Industries:
-
March 25, 2021
Mitsubishi Beats Bid To Invalidate Diabetes Drug Patents
A New Jersey federal judge has refused to invalidate patents for Mitsubishi Tanabe Pharma Corp.'s diabetes drugs Invokana and Invokamet, striking down Zydus Pharmaceuticals Ltd.'s bid to dodge patent infringement claims over its plan to roll out generic versions.
-
November 25, 2020
Zydus Insists Mitsubishi Doesn't Deserve Diabetes Patents
Zydus Pharmaceuticals punctuated the six-day trial in its bid to bring generic diabetes drugs to market by filing a 100-page, post-trial brief doubling down on its claim that Mitsubishi Tanabe Pharma Corp. is engaging in "gamesmanship" to extend the life of one of three patents Zydus is accused of infringing.
-
November 05, 2020
Testimony In NJ Zoom Trial Wraps In Diabetes Drug IP Row
On the last day of trial testimony in Mitsubishi Tanabe Pharma Corp.'s infringement suit that seeks to stop Zydus from bringing generic diabetes drugs to market, Zydus said Thursday "the law is crystal clear" that one of three patents it's accused of infringing is invalid.
-
May 01, 2020
COVID-19 IP Catch-Up: Looming Trials, Jeff Dunham's Dummy
The copyright and patent offices have pushed back certain deadlines as the COVID-19 pandemic continues, while at least one intellectual property bench trial is about to proceed over video. Here, Law360 pulls together all the updates you might have missed, including victories for 3M in its trademark campaign and a new suit by comedian Jeff Dunham seeking to protect his image.
-
June 07, 2019
InvaGen Agrees To Admit Infringing Diabetes Drug To End Suit
Pharmaceutical companies Mitsubishi Tanabe Pharma Corp., Janssen Pharmaceuticals Inc. and Cilag GmbH International have asked a New Jersey federal judge to sign off on their deal to drop a patent infringement lawsuit against InvaGen Pharmaceuticals Inc. over its application for the generic version of Janssen's diabetes treatment Invokamet.